GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...